Physiologic and pathophysiologic relevance of T-type calcium-ion channels: Potential indications for T-type calcium antagonists

Clinical Therapeutics

Volumn 19, Issue SUPPL. A, 1997, Pages 18-26

  Hermsmeyer, Kent ^a   Mishra, Santosh ^a   Miyagawa, Koichi ^a   Minshall, Richard ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Calcium antagonists; Calcium ion channels; Cardioprotection; Mibefradil

Indexed keywords

CALCIUM ANTAGONIST; CALCIUM CHANNEL; MIBEFRADIL;

BLOOD VESSEL TONE; DRUG EFFECT; HEART DISEASE; HEART PROTECTION; HUMAN; INOTROPISM; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; SINUS NODE;

EID: 0030663243     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80034-3     Document Type: Article

References (33)

1. Tsien R, Tsien R. Calcium channels, stores, and oscillations. Annu Rev Cell Biol. 1990;6:715-760.
2. 2+ channels and their possible counterparts in mammalian CNS neurons. Neuropharmacology. 1993;32:1075-1088.
3. 2+ channel antagonists. Trends Pharmacol Sci. 1992;13:256-262.
4. Sturek M, Hermsmeyer K. Calcium and sodium channels in spontaneously contracting vascular muscle cells. Science. 1986;233:475-478.
5. Triggle D. Calcium channel drugs: Structure-function relations and selectivity of action. J Cardiovasc Pharmacol. 1991;18 (Suppl 10):S1-S6.
6. Hermsmeyer K. Ion channels as targets for drugs. In: Sperelakis N, ed. Cell Physiology Source Book. San Diego: Academic Press; 1995:404-412.
7. Bean B. Pharmacology of calcium channels in cardiac muscle, vascular muscle, and neurons. Am J Hypertens. 1991;4(Suppl):406S-411S.
8. 2+ channels by Ro 40-5961. Circ Res. 1994;75:144-148.
9. Naylor W. The molecular biology of the voltage-dependent, calcium antagonist-sensitive calcium channels. In: Second Generation of Calcium Antagonists. New York: Springer-Verlag; 1991:25-37.
10. Bean BP. Classes of calcium channels in vertebrate cells. Am Rev Physiol. 1989;51:367-384.
11. 2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol. 1995;48:540-549.
12. 2+ channels. Trends Pharmacol Sci. 1991;12:349-354.
13. 2+ in dog coronary arterial vascular muscle cells by Ro 40-5967. J Cardiovasc Pharmacol. 1994;24:1-7.
14. 2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res. 1993;73:777-782.
15. Zhou Z, Lipsius S. T-type calcium current in latent pacemaker cells isolated from cat right atrium. J Mol Cell Cardiol. 1994;26:1211-1219.
16. 2 receptor inhibition of the T-type calcium current in non-differentiated NG108-15 cells. J Biol Chem. 1995;270:1670-1674.
17. DeGasparo M, Bottari S, Levens N. Characteristics of angiotensin II receptors and their role in cell and organ physiology. In: Laragh J, Brenner B, eds. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed. New York: Raven Press; 1995:1695-1720.
18. Furukawa T, Ito H, Nitta M, et al. Endothelin-I enhances calcium entry through T-type channels in cultivated neonatal rat ventricular myocytes. Circ Res. 1992;71:1242-1253.
19. Kawano S, DeHaan RL. Low threshold current is major calcium current in chick ventricular cells. Am J Physiol. 1989;256(Suppl):H1505-H1508.
20. Gray G, Clozel M, Clozel J, Baumgartner H-R. Effects of calcium channel blockade on the aortic intima in spontaneously hypertensive rats. Hypertension. 1993;22:569-576.
21. Véniant M, Clozel J-P, Hess P, Wolfgang R. Ro 40-5967, in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction. J Cardiovasc Pharmacol. 1991;17:277-284.
22. Clozel J-P, Banken L, Osterrieder W. Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: Comparison with verapamil. J Cardiovasc Pharmacol. 1989;14:713-721.
23. Onto K, Satoh K, Taira N. Cardiovascular profile of Ro 40-5967, a new nondihydropyridine calcium antagonist, delineated in isolated, blood-perfused dog hearts. J Cardiovasc Pharmacol 1993;22:293-299.
24. Guth B. Reduction of exercise-induced regional contractile dysfunction in dogs using a novel calcium channel blocker (Ro 40-5967). Cardiovasc Drugs Ther. 1992;6:167-171.
25. Billman G. Ro 40-5967, a novel calcium channel antagonist, protects against ventricular fibrillation. Eur J Pharmacol. 1992;229:179-187.
26. Schmitt R, Kleinbloesem C, Belz G, et al. Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther. 1992;52:314-323.
27. Stea A, Soong T, Snutch T. Determinants of PKC-dependent modulation of a family of neuronal calcium channels. Neuron. 1995;15:929-940.
28. Schmitt R, Clozel J-P, Iberg N, Buhler F. Mibefradil prevents neointima formation after vascular injury in rats: Possible role of the blockade of the T-type voltage-operated calcium channel. Arterioscler Thromb Vasc Biol. 1995;15:1161-1165.
29. 2+ antagonist, Ro 40-5967. J Vasc Res. 1996;33:71-77.
30. 3H] dihydropyridine binding by activation of protein kinase C in vascular smooth muscle. Eur J Pharmacol. 1991;208:223-230.
31. Ménard J, Karam H, Véniant M, et al. Effects of calcium blockade on end-organ damage in experimental hypertension. J Hypertens. 1997;15(Suppl 3):S19-S30.
32. Mulder P, Richard V, Compagnon P, et al. Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure. J Am Coll Cardiol. 1997;29:416-421.
33. Levine T. The design of the Mortality Assessment in Congestive Heart Failure trial (MACH-1, Mibefradil). Clin Cardiol. 1997;20:320-326.